A multi-centre, double-blind, randomised, placebo-controlled trial, of oral anticoagulation with apixaban in participants with Systemic Sclerosis-related Pulmonary Arterial Hypertension, measuring time to clinical worsening of Pulmonary Arterial Hypertension.

Trial Profile

A multi-centre, double-blind, randomised, placebo-controlled trial, of oral anticoagulation with apixaban in participants with Systemic Sclerosis-related Pulmonary Arterial Hypertension, measuring time to clinical worsening of Pulmonary Arterial Hypertension.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Apixaban (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Acronyms SPHInX
  • Most Recent Events

    • 27 Apr 2017 Planned End Date changed from 4 Dec 2017 to 31 Dec 2021.
    • 21 May 2015 Status changed from not yet recruiting to recruiting as per Australian New Zealand Clinical Trials Registry.
    • 02 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top